{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:06:19Z","timestamp":1785539179409,"version":"3.56.0"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T00:00:00Z","timestamp":1566086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This randomised, double\u2010blind, placebo\u2010controlled trial assessed\u00a0the efficacy, safety and tolerability of voriconazole+anidulafungin (combination) or voriconazole+placebo (monotherapy) for invasive aspergillosis (<jats:styled-content style=\"fixed-case\">IA<\/jats:styled-content>;<jats:styled-content style=\"fixed-case\"> NCT<\/jats:styled-content>00531479). We present a post hoc analysis of Korean and non\u2010Korean patients with <jats:styled-content style=\"fixed-case\">IA<\/jats:styled-content> (including baseline positive serum galactomannan [<jats:styled-content style=\"fixed-case\">GM<\/jats:styled-content>]). Immunocompromised patients\u00a0\u2265\u00a016\u00a0years with <jats:styled-content style=\"fixed-case\">IA<\/jats:styled-content> were randomised 1:1, combination or monotherapy, for\u00a0\u2265\u00a02\u00a0weeks\u2019 treatment. The primary endpoint was 6\u2010 and 12\u2010week all\u2010cause mortality (Korean modified intent\u2010to\u2010treat [<jats:styled-content style=\"fixed-case\">mITT<\/jats:styled-content>] population). Overall, 454 patients enrolled (Koreans: 56 [combination: 28, monotherapy: 28], non\u2010Koreans: 398 [combination: 200, monotherapy: 198]). The <jats:styled-content style=\"fixed-case\">mITT<\/jats:styled-content> population comprised 40 Koreans (combination: 23; monotherapy: 17) and 237 non\u2010Koreans (combination: 112; monotherapy: 125). Week 6 treatment difference in mortality rate between combination and monotherapy was \u22126.4% in non\u2010Koreans. This reduction was more marked in Koreans (\u221222.4%). Week 12 difference in all\u2010cause mortality between combination and monotherapy was \u221217.7% (Koreans) and \u221220.2% at Week 6 (Koreans; positive baseline <jats:styled-content style=\"fixed-case\">GM<\/jats:styled-content>). Week 6 mortality (Koreans [<jats:styled-content style=\"fixed-case\">mITT<\/jats:styled-content>]; baseline <jats:styled-content style=\"fixed-case\">GM<\/jats:styled-content> &gt;0.5\u20102.0) was 0\/13 (combination) and 2\/6 (monotherapy). Serious adverse events were numerically higher for combination than monotherapy (Koreans: 57.1%, 46.4%; non\u2010Koreans: 49.5%, 46.0%). In Koreans, combination therapy was associated with marginally better outcomes than monotherapy and more so than in non\u2010Koreans.<\/jats:p>","DOI":"10.1111\/myc.12972","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T14:34:12Z","timestamp":1564410852000},"page":"969-978","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis"],"prefix":"10.1111","volume":"62","author":[{"given":"Dong\u2010Gun","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Internal Medicine College of Medicine The Catholic University of Korea Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye\u2010Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Pfizer Inc Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Li","family":"Yan","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Sheng\u2010Fong","family":"Lin","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/320871"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/510592"},{"key":"e_1_2_9_5_1","unstructured":"Astellas.AmBisome prescribing information; revised July 2018. 2018.https:\/\/www.astellas.us\/docs\/ambisome.pdf. Accessed July 11 2018."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"},{"key":"e_1_2_9_7_1","first-page":"237","article-title":"Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5\u2010year retrospective cohort study","volume":"55","author":"Kim SB","year":"2017","journal-title":"Med Mycol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1232-1235.2005"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.970-978.2004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2564-2568.2002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3572-3574.2005"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/423380"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.08.012"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2508"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/343804"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/528714"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.116181"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.38"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.126"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.194"},{"key":"e_1_2_9_22_1","first-page":"604","article-title":"Differences in the incidence of the CYP2C19 polymorphism affecting the S\u2010mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele","volume":"281","author":"Xiao ZS","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.4.406"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008327537"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.02.002"},{"key":"e_1_2_9_26_1","unstructured":"FDA Antiviral Drugs Advisory Committee.FDA Briefing document for voriconazole. 2001.https:\/\/wayback.archive-it.org\/7993\/20170405165747\/https:\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3792b2_02_FDA-voriconazole.pdf. Accessed November 7 2018."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0835-0"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw276"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02809-13"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1400"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06513-11"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.1.61"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01025-13"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090176"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-018-0271-8"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.12972","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T22:49:59Z","timestamp":1694299799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,18]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/myc.12972"],"URL":"https:\/\/doi.org\/10.1111\/myc.12972","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,18]]},"assertion":[{"value":"2019-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}